RecruitingNot ApplicableNCT07226193

Detecting Peripheral Artery Disease With the Pulse

Pulse Arrival Time as an Alternative Biomarker to Detect Lower-Extremity Peripheral Artery Disease


Sponsor

University of Nebraska

Enrollment

40 participants

Start Date

Feb 5, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to both middle fingers and both big toes. Signals will be collected for 15-min with finger and toe sensor temperatures at 30 C. Toe sensor temperature will then be elevated to 45 C for 15-min. Finally, toe sensor temperature will remain at 45 C, and the feet will be elevated 8-in with a soft cushion for 15-min. Blood pressure in the foot will be assessed before and after foot elevation with Doppler ultrasound. Thermal images of the fingers and toes will be assessed before and after using the investigational device. Subjects will then participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last \~2.5hrs. 4) There will be no follow-up.


Eligibility

Min Age: 19 Years

Inclusion Criteria3

  • be able to provide written informed consent
  • be 19 years of age or older
  • having or not having a diagnosis of peripheral artery disease

Exclusion Criteria5

  • having a current or pervious aortic aneurysm with or without previous intervention
  • having previous revascularization surgeries (open or endovascular) of the legs or aorta
  • having walking impairments independent of lower-limb ischemia (e.g., musculoskeletal injury)
  • having gangrene or ulcers of the toes/feet
  • being currently pregnant or breastfeeding

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESegmental pulse arrival time assessment

A proprietary device has been developed to obtain segmental pulse arrival times in the arms and legs. Using this information, the propagation time of the pulse is being investigated as a biomarker to detect the presence of lower-extremity atherosclerosis. Furthermore, the impacts of aging on the biomarker will be assessed.


Locations(1)

University of Nebraska at Omaha Health Science Collaborative

Omaha, Nebraska, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07226193


Related Trials